natgillin/translations-raw huggingface dataset:
a bore or passageway (18) extending through the plastic body portion (12) and having a first opening proximate the first end (16) and a second opening at the second end (14); and 
provrta ili prolaza (18) koji prolazi kroz plastični dio tijela (12) i ima prednji otvor koji je u blizini prednjeg kraja (16) i stražnji otvor na stražnjem kraju (14);
The injection nozzle according to claim 1, wherein the plurality of channels (22) are arranged in a dispersing pattern from the first opening, in particular to subscribe an arc of about sixty degrees. 
Mlaznica za injektiranje prema zahtjevu 1, naznačena time da je mnoštvo kanala (22) raspoređeno tako da se šire od prednjeg otvora, naročito tako da opisuju luk od oko šezdeset stupnjeva.
The injection nozzle according to at least one of claims 1 to 3, wherein the first end (16) comprises a facial portion in which the apertures (24) are disposed. 
Mlaznica za injektiranje prema barem jednom od zahtjeva 1 do 3, naznačena time da prednji kraj (16) sadrži prednji dio u kojem su raspoređeni otvori (24).
The injection nozzle according to at least one of claims 1 to 5, wherein the plastic body portion (12) comprises an, in particular metallic, threaded portion at the second end (14) for being releasably engaged to an, in particular mechanical, fastener. 
Mlaznica za injektiranje prema barem jednom od zahtjeva 1 do 5, naznačena time da plastični dio tijela (12) sadrži, naročito metalni, navojni dio na stražnjem kraju (14) u svrhu rastavljivog povezivanja sa, naročito mehaničkom, spojnicom.
is constructed of the same material as the plastic body portion (12) or 
od istog materijala kao plastični dio tijela (12) ili
extends from a flange or washer (20), with which a section of the plastic body portion (12) is provided. 
proteže se od prirubnice ili podloške (20), koja se nalazi na jednom dijelu plastičnog dijela tijela (12).
The injection nozzle according to claim 9, wherein the housing or sheath (30) is a metallic housing or metallic sheath. 
Mlaznica za injektiranje prema barem jednom od zahtjeva 1 do 7, naznačena time da kućište ili omotač (30) je metalno kućište ili metalni omotač.
The injection nozzle according to claim 4 or 5 and to claim 9 or 10, wherein the housing or sheath (30), in particular the sidewall, comprises a facial portion (36) in registration with the facial portion of the first end (16). 
Mlaznica za injektiranje prema zahtjevu 4 ili 5, te naročito prema barem jednom od zahtjeva 2 ili 3 ili 6 do 8, naznačena time da kućište ili omotač (30), naročito bočna stjenka, sadrži prednji dio (36) u kontaktu s prednjim dijelom prednjeg kraja (16).
The injection nozzle according to claim 9, wherein the facial portion (36) of the housing or sheath (30) is an angularly cut facial portion and/or an angled metallic facial portion. 
Mlaznica za injektiranje prema zahtjevu 9, naznačena time da prednji dio (36) kućišta ili omotača (30) predstavlja prednji dio odsječen pod kutom i/ili pod kutom nakošen metalni prednji dio.
Formulation for use in prophylaxis of oral cavity diseases in the form of a toothpaste comprising glycerol, silica, calcium glycerophosphate, methylparaben, propylparaben, titanium dioxide, perfume, sodium saccharate, sodium lauryl sulfate or alkylamidobetain, and drinking water, characterized in that it further comprises proteolytic enzyme bromelain, natural sweetener xylitol, xanthan gum, and magnesium chloride or magnesium glycerophosphate, at the following component ratio, % wt.: 
Formulacija za uporabu u prevenciji bolesti usne šupljine u obliku zubne paste koja sadrži glicerol, siliku, kalcijev glicerofosfat, metilparaben, propilparaben, titanijev dioksid, parfem, natrijev saharat, natrijev lauril sulfat ili alkilamidobetain i vodu za piće, naznačena time što dalje sadrži proteolitički enzim bromelain, prirodni zaslađivač ksilitol, ksantan gumu i magnezijev klorid ili magnezijev glicerofosfat, u sljedećim omjerima prema postotku masenog udjela:
The compound for use of claim 9 wherein the chronic kidney disease is glomerulonephritis, focal segmental glomerulosclerosis, nephrotic syndrome, reflux uropathy, or polycystic kidney disease. 
Spoj za uporabu prema zahtjevu 9, naznačen time da kronična bolest bubrega je glomerulonefritis, fokalna segmentna glomeruloskleroza, nefrotski sindrom, refluks uropatija ili policistična bolest bubrega.
An immunoconjugate comprising an antibody or antigen-binding fragment thereof covalently attached to a cytotoxic agent, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof that binds to CD22 and comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO:16, and a light chain variable domain having the amino acid sequence of SEQ ID NO:18, and wherein the antibody or antigen-binding fragment thereof further comprises a cysteine at position 205 of the light chain according to Kabat numbering convention or position 118 of the heavy chain according to EU numbering convention. 
Imunokonjugat koji sadrži protutijelo ili njegov fragment koji se veže na antigen, naznačen time, da je kovalentno priključen na citotoksični agens, pri čemu je to protutijelo ili njegov fragment koje/i se veže na antigen, monoklonalno protutijelo ili njegov fragment koji se veže na antigen, koje/i se veže na CD22 i sadrži varijabilnu domenu jakog lanca, koja ima aminokiselinsku sekvencu od SEQ ID NO:16, i varijabilnu domenu slabog lanca, koja ima aminokiselinsku sekvencu od SEQ ID NO:18, te pritom protutijelo ili njegov fragment koji se veže na antigen, nadalje sadrži cistein na poziciji 205 od slabog lanca u skladu s Kabat-konvencijskim numeriranjem ili na poziciji 118 od jakog lanca u skladu s EU-konvencijskim numeriranjem.
a heavy chain sequence selected from any one of SEQ ID NOS:88 or 92; 
sekvencu jakog lanca odabranu od bilo koje od SEQ ID NO:88 ili SEQ ID NO:92;
The immunoconjugate of any one of claims 1 to 6, wherein the cytotoxic agent is selected from a toxin, a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme. 
Imunokonjugat prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je citotoksični agens odabran od sljedećih: toksin, kemoterapeutsko sredstvo, dio molekule lijeka, antibiotik, radioaktivni izotop, i nukleolitički enzim.
L is a linker comprising one or more linker components; 
L je poveznica koja sadrži jedan ili više veznih sastojaka;
D is a drug moiety. 
D je dio molekule lijeka.
A is a Stretcher unit covalently attached to a cysteine thiol of the cysteine engineered antibody (Ab); a is 0 or 1; 
A je prenosiva jedinica kovalentno priključena na cistein-tiol od cisteinski modificiranog protutijela (Ab); a je 0 ili 1;
having the formula:; or 
ima sljedeću formulu: [image]; ili
having the formula: 
ima sljedeću formulu:
The pharmaceutical composition of claim 16 for use in a method of treating a B cell proliferative disorder. 
Farmaceutski sastav prema zahtjevu 16, naznačen time, da ose upotrebljava u postupku liječenja proliferativnog poremećaja B-stanice.
The pharmaceutical composition of claim 16 for the use of claim 17, wherein the B cell proliferative disorder is selected from lymphoma, non-Hogkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma. 
Farmaceutski sastav prema zahtjevu 16 za uporabu prema zahtjevu 17, naznačen time, da je proliferativni poremećaj B-stanice odabran od sljedećih: limfom, non-Hodgkinov limfom (NHL), agresivni NHL, recidivni agresivni NHL, recidivni indolentni NHL, otporan NHL, otporan indolentni NHL, kronična limfocitna leukemija (CLL), mali limfocitni limfom, leukemija, leukemija kosmatih stanica (HCL), akutna limfocitna leukemija (ALL), limfom plaštenih stanica.
The expansion joint according to claim 1, wherein the dividing member (4) in the upper portion is either a vertically oriented straight plate, such as for example an L-profile, or a vertically oriented corrugated plate (4). 
Kompenzacijski spoj prema zahtjevu 1, naznačen time da razdjelni element (4) u gornjem dijelu ili je vertikalna ravna ploča, kao što je na primjer L-profila, ili je vertikalno usmjerena valovita ploča (4).
An expansion joint according to claim 1 wherein the dividing member (4) is a vertically oriented corrugated plate (4), characterized in that the corrugated plates of the upper (4) and lower (5, 17) portion are out of phase to one another. 
Kompenzacijski spoj prema zahtjevu 1 gdje razdjelni element (4) je vertikalno postavljena valovita ploča (4), naznačen time da valovite ploče gornjeg (4) i donjeg (5, 17) dijela su međusobno pomaknute u fazi.
The expansion joint according to claim 3, wherein the corrugation of the upper (4) and lower plates (5, 17) is the same. 
Kompenzacijski spoj prema zahtjevu 3, naznačen time da je valovitost gornje (4) i donje ploče (5, 17) ista.
The expansion joint according to any one of claims 1 to 4, wherein the corrugation consists of a waveform. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time da se naboranost sastoji od valovitog oblika.
The expansion joint according to any one of claims 3 to 5, wherein the upper (4) and first lower (5) corrugated plates are in substantially the same lateral plane. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 3 do 5, naznačen time su gornje (4) i prve donje (5) valovite ploče u osnovi u istoj bočnoj ravnini.
The expansion joint according to claim 8, wherein the corrugated plates and the dividing member (4) are secured to one another through a binding member (8). 
Kompenzacijski spoj prema zahtjevu 8, naznačen time da su valovite ploče i razdjelni element (4) međusobno pričvršćeni preko veznog elementa (8).
The expansion joint according to any one of claims 3 to 9, wherein the upper portion (2) further comprises a second dividing member, such as a second vertically oriented corrugated plate (6) that fits within the undulations (11) of the vertically oriented corrugated plate (4) of the upper portion. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 3 do 9, naznačen time da gornji dio (2) nadalje sadrži drugi razdjelni element, kao što je druga okomito orijentirana valovita ploča (6), koja se uklapa unutar nabora (11) okomito orijentirane valovite ploče (4) gornjeg dijela.
The expansion joint according to claims 10-11, wherein said second corrugated plate (17) of the lower portion is in substantially the same lateral plane as the second corrugated plate (6) of the upper portion. 
Kompenzacijski spoj prema zahtjevima 10 -11, naznačen time da je navedena druga valovita ploča (17) od donjeg dijela u istoj bočnoj ravnini kao i druga valovita ploča (6) gornjeg dijela.
The expansion joint according to claim 14, wherein the second upper (6) and lower (17) corrugated plates are secured to one another through a binding member (8). 
Kompenzacijski spoj prema zahtjevu 14, naznačen time da su druge gornje (6) i donje valovite ploče (17) međusobno pričvršćene preko veznog elementa (8).
The expansion joint according to any one of claims 1 to 15, wherein the dividing members (4, 6) of the upper portion and the corrugated plates (5, 17) of the lower portion are formed of a substantially rigid material; in particular a metallic material; more in particular steel. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time da su razdjelni elementi (4, 6) gornjeg dijela i valovite ploče (15, 17) donjeg dijela oblikovani od u biti čvrstog materijala; posebno od metalnog materijala; posebno od čelika.
A pharmaceutical composition comprising a compound of formula: or a pharmaceutically acceptable salt thereof; wherein: T, U, and V are independently selected from O, S, N, CR5, and NR6; 
Farmaceutski sastav koji sadrži spoj formule: [image] ili njegovu farmaceutski prihvatljivu sol, pri čemu: T, U i V su nezavisno izabrani od O, S, N, CR5, i NR6;
The pharmaceutical composition of claim 1, wherein the compound is a compound of Formula II: or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav prema zahtjevu 1, pri čemu je spoj spoj Formule II: [image] ili njegova farmaceutski prihvatljiva sol.
The pharmaceutical composition of claim 1 or 2, wherein X is N. 
Farmaceutski sastav prema zahtjevu 1 ili 2, pri čemu X je N.
The pharmaceutical composition of any one of claims 1 to 3, wherein n is 0. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu n je 0.
The pharmaceutical composition of any one of claims 1 to 3, wherein n is 1 and Y is C1-8 alkylene optionally substituted with 1, 2, or 3 halo, OH, CN, amino, C1-4 alkylamino, or C2-8 dialkylamino. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu n je 1 i Y je C1-8 alkilen opcionalno supstituiran s 1, 2 ili 3 halo, OH, CN, amino, C1-4 alkilamino, ili C2-8 dialkilamino.
The pharmaceutical composition of claim 1, wherein said compound is selected from: 
Farmaceutski sastav prema zahtjevu 1, pri čemu je navedeni spoj izabran od:
A pharmaceutical composition comprising a compound which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein said composition is suitable for oral administration and for providing sustained release of said compound or said salt. 
Farmaceutski sastav koji sadrži spoj koji je 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
A pharmaceutical composition comprising a compound which is (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein said composition is suitable for oral administration and for providing sustained release of said compound or said salt. 
Farmaceutski sastav koji sadrži spoj koji je (R)-3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
A pharmaceutical composition comprising a compound which is 3-cyclopropyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-1-yl]-propionitrile; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein said composition is suitable for oral administration and for providing sustained release of said compound or said salt. 
Farmaceutski sastav koji sadrži spoj koji je 3-ciklopropil-3-[4-(7H-pirolo[2,3-d]pirimidin-4il)-pirazol-1-il]-propionitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
The pharmaceutical composition of any one of claims 1 to 11, wherein said composition is a unit dosage form. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je navedeni sastav oblika jedinice doziranja.
The pharmaceutical composition of claim 12, wherein said unit dosage form further comprises an enteric coating. 
Farmaceutski sastav prema zahtjevu 12, pri čemu navedeni oblik jedinice doziranja dalje sadrži enteričnu oblogu.
The pharmaceutical composition of claim 12, wherein the unit dosage form comprises from about 5 to about 1000 mg of said compound or said salt. 
Farmaceutski sastav prema zahtjevu 12, pri čemu navedeni oblik jedinice doziranja sadrži od oko 5 do oko 1000 mg navedenog spoja ili navedene soli.
The pharmaceutical composition of any one of claims 1 to 11, wherein said carrier comprises one or more excipients selected from lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu navedeni nosač sadrži jedan ili više ekscipijenata izabranih od laktoze, dekstroze, saharoze, sorbitola, manitola, škrobova, gume akacije, kalcijevog fosfata, alginata, tragakanta, želatine, kalcijevog silikata, mikrokristalične celuloze, polivinilpirolidona, celuloze, vode, sirupa i metil celuloze.
The pharmaceutical composition of any one of claims 1 to 11, wherein said carrier comprises microcrystalline cellulose. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu navedeni nosač sadrži mikrokristaličnu celulozu.
The pharmaceutical composition of any one of claims 1 to 11, wherein said carrier comprises lactose. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, pri čemu navedeni nosač sadrži laktozu.
The pharmaceutical composition of any one of claims 1 to 11, for use in a method of treating a disease selected from cachexia, a myeloproliferative disorder, and cancer in a patient. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 do 11, za uporabu u postupku liječenja bolesti izabranih od kaheksije, mijeloproliferativnog poremećaja i raka kod pacijenta.
The pharmaceutical composition for use according to claim 20, wherein the disease is a myeloproliferative disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 20, pri čemu je bolest mijeloproliferativni poremećaj.
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is polycythemia vera (PV). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj policitemija vera (PV).
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is essential thrombocythemia (ET). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj esencijalna trombocitemija (ET).
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj mijeloidna metaplazija s mijelofibrozom (MMM).
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is chronic myelogenous leukemia (CML). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj kronična mijeloična leukemija (CML).
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is chronic myelomonocytic leukemia (CMML). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj kronična mijelomonocitna leukemija (CMML).
The pharmaceutical composition for use according to claim 21, wherein said disease is cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je navedena bolest rak.
The pharmaceutical composition for use according to claim 28, wherein said cancer is multiple myeloma. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak multipli mijelom.
The pharmaceutical composition for use according to claim 28, wherein said cancer is leukemia. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak leukemija.
The pharmaceutical composition for use according to claim 28, wherein said cancer is lymphoma. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak limfom.
The pharmaceutical composition for use according to claim 28, wherein said cancer is acute myelogenous leukemia. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak akutna mijeloična leukemija.
The pharmaceutical composition for use according to claim 28, wherein said disease is breast cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedena bolest rak dojke.
The pharmaceutical composition for use according to claim 28, wherein said cancer is lung cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak pluća.
The pharmaceutical composition for use according to claim 28, wherein said cancer is cancer of the head and neck. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak rak glave i vrata.
The pharmaceutical composition for use according to claim 28, wherein said cancer is selected from prostate cancer, renal cancer, hepatic cancer, gastric cancer, thyroid cancer, glioblastoma, Karposi's sarcoma, Castleman's disease, melanoma, cutaneous T-cell lymphoma (CTCL), cutaneous B-cell lymphoma, Sezary syndrome, mycosis fungoides, acute lymphoblastic leukemia, and colorectal cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak izabran od raka prostate, raka bubrega, raka jetre, raka želuca, raka štitne žlijezde, glioblastoma, Kaposijevog sarkoma, Castlemanove bolesti, melanoma, T-staničnog kožnog limfoma (CTCL), B-staničnog kožnog limfoma, Sezary sindroma, "mycosis fungoides" (kronični T-stanični limfom), akutne limfoblastične leukemije i kolorektalnog raka.
The pharmaceutical composition for use according to claim 20, wherein said cachexia results from or is associated with cancer. 
Farmaceutski sastav za upotrebu prema zahtjevu 20, pri čemu navedena kaheksija proizlazi iz ili je povezana s rakom.
A compound represented by the general formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C1 to C6 alkylsulfinyl group, a C1 to C6 alkylsulfinyl group, a C1 to C6 alkylsulfonyl group, or a C1 to C6 alkoxy-C1 to C6 alkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group. 
Spoj prikazan općom formulom (1) ili njegova farmaceutski prihvatljiva sol: [image] naznačen time da su R1 i R2 svaki neovisno vodikov atom, atom halogena, amino skupina, hidroksil skupina, hidroksilamino skupina, nitro skupina, cijano skupina, sulfamoil skupina, C1 do C6 alkil skupina, C1 do C6 alkoksi skupina, C1 do C6 alkilsulfanil skupina, C1 do C6 alkilsulfinil skupina, C1 do C6 alkilsulfonil skupina, C1 do C6 alkoksi-C1 do C6alkilsulfonil skupina i A je supstituirana ili nesupstituirana heteroaril skupina.
The compound according to any of claims 1 to 8 or a pharmaceutically acceptable salt thereof, wherein A is an unsubstituted heteroaryl group or a heteroaryl group that is mono-substituted with a halogen atom, a C1 to C6 alkyl group optionally substituted with a halogen atom or a hydroxyl group, a C1 to C6 alkoxy group optionally substituted with a halogen atom or a hydroxyl group, a nitro group, a cyano group, or a group represented by the formula of - -(O)p(CH2)mC(O)OR3 (wherein R3 is a hydrogen atom or a C1 to C6 alkyl group, m is an integer of 0 to 2, and p is 0 or 1). 
Spoj prema bilo kojem od zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, naznačen time da je A nesupstituirana heteroaril skupina ili heteroaril skupina koja je mono supstituirana sa atomom halogena, C1 do C6 alkil skupinom proizvoljno supstituiranom s atomom halogena ili hidroksil skupinom, C1 do C6 alkoksi skupina proizvoljno supstituirana s atomom halogena ili hidroksil skupinom, nitro skupinom, cijano skupinom, ili skupinom prikazanom formulom –(O)p(CH2)mC(O)OR3, pri čemu je R3 atom vodika ili C1 do C6 alkil skupina, m je cijeli broj od 0 do 2 i p je 0 ili 1.